PreEvnt
PreEvnt, a subsidiary of Scosche Industries, is developing isaac, a watch-sized wearable that non-invasively estimates blood glucose from exhaled breath via VOC/acetone sensing, targeting Type 1 and Type 2 diabetics, prediabetics, and health-conscious consumers pending FDA De Novo clearance.
- Company typePrivate
- Founded2024
- HeadquartersOxnard, United States
- Headcount1–10
- GTM typeB2C
- OfferingHardware or Manufacturing
What PreEvnt does
PreEvnt, a 2024-founded subsidiary of Scosche Industries headquartered in Oxnard, California, is developing isaac, a wearable, non-invasive glucose monitoring device intended for Type 1 and Type 2 diabetics, prediabetics, and health-conscious consumers. The device is approximately the size of a 2-euro coin and uses Volatile Organic Compound (VOC) detection — specifically acetone in exhaled breath — via licensed, patented selective gas-sensing Metal Oxide (MOx) sensor technology from Nanoz to estimate blood glucose levels and trigger alerts, eliminating the need for finger-prick blood tests. A rechargeable lithium battery powers all-day use with a USB-C cradle, and the device is designed to pair with a free companion iOS/Android app that logs readings, delivers real-time alerts (including to designated emergency contacts via text/email), and generates shareable CSV reports with diet and exercise notes.
The go-to-market is direct-to-consumer: PreEvnt operates a Shopify-based e-commerce storefront at preevnt.com, plans to sell through iOS and Android app marketplaces, and is positioning isaac against the OTC continuous glucose monitor category currently led by Abbott and Dexcom. Commercial revenue has not yet begun because the device is undergoing FDA De Novo review with targeted approval in 2027 and a planned Q4 2026 launch; human clinical trials are running at Indiana University Indianapolis under Dr. M. Agarwal. Revenue mechanics will combine hardware unit sales with potential future subscription or premium app services.
PreEvnt's strategic posture is that of a regulated medical-device challenger: it is assembling an ecosystem of clinical evidence (Indiana University), proprietary sensing IP (Nanoz licensing), consumer distribution (Scosche Industries parentage, CES-driven brand presence), and a regulatory pathway (FDA De Novo). The company has no disclosed external funding, no disclosed revenue, and no commercial customers as of the input data; its near-term trajectory is gated almost entirely by the FDA outcome rather than by go-to-market execution.
PreEvnt firmographics
Firmographics- Name
- PreEvnt
- Legal name
- PreEvnt
- Website
- https://PreEvnt.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- PreEvnt, a subsidiary of Scosche Industries, is developing isaac, a watch-sized wearable that non-invasively estimates blood glucose from exhaled breath via VOC/acetone sensing, targeting Type 1 and Type 2 diabetics, prediabetics, and health-conscious consumers pending FDA De Novo clearance.
- Ownership category
- akta.pro rank
PreEvnt industry classification
Industry- Product category
- Non-Invasive Glucose Monitoring Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
- akta.pro secondary industry
- Diabetes (General) (HLAKADAA)
Keywords
Where PreEvnt is headquartered
LocationHeadquarters
- HQ city
- Oxnard
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PreEvnt business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Operations, Marketing or Sales, Personnel
Revenue model
- Hardware Device Sales: PreEvnt generates revenue from sales of the Isaac hardware device - a wearable breath-based glucose monitor. The device is not yet available for sale as it undergoes FDA review.
- Mobile Application Services: Free companion mobile app for iOS and Android that collects breath test results, sends alert notifications, and generates shareable reports. Revenue potential from premium app features or services post-launch.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
PreEvnt product offering
Product offeringCore offering
PreEvnt develops, manufactures (via parent Scosche Industries), and intends to sell "isaac," a non-invasive, wearable breath-based glucose-monitoring device that detects acetone (a VOC) in exhaled breath to alert users to elevated blood glucose levels without finger-prick blood tests. It is paired with a free iOS/Android companion app that logs readings, dispatches real-time alerts (including to emergency contacts), and exports shareable reports. The product is not yet commercially available as it is undergoing FDA De Novo review, with human clinical trials at Indiana University Indianapolis supporting the regulatory pathway.
Product overview
PreEvnt, a subsidiary of Scosche Industries based in Oxnard, California, offers a unified product ecosystem centered on the isaac non-invasive glucose monitoring device and its companion mobile app. The isaac wearable hardware and the isaac mobile app work together as an integrated system—the device captures breath-based VOC readings while the app logs data, delivers alerts, and generates shareable health reports.
Differentiator
Problem solved
Functional benefit
Brands
- isaac: Non-invasive blood glucose alert device that uses volatile organic compound (VOC) detection, specifically acetone, from exhaled breath to determine and alert users to elevated blood glucose levels. The device is wearable, watch-sized, and comes with a mobile app for iOS and Android.
Products and services
- isaac by PreEvnt non-invasive glucose monitor A small, watch-sized, rechargeable wearable that uses Volatile Organic Compound (VOC) detection, specifically acetone from exhaled breath, to estimate blood glucose levels and alert users to elevated readings. It reduces or replaces the need for finger-prick blood tests, comes with a USB-C charging cradle, lanyard, and pocket clip, and pairs with the isaac app to log readings and forward alerts. Aimed at people with Type 1 diabetes, Type 2 diabetes, pre-diabetes, and health-conscious consumers.
- isaac by PreEvnt companion mobile app A free iOS and Android smartphone application that works with the isaac wearable to collect breath-test results, record contextual notes (diet, exercise, time, date), trigger real-time alerts to the user and to designated emergency contacts via text and/or email, and export longitudinal reports in CSV that can be shared with parents, partners, or physicians.
Quantifiable outcome
- Device is approximately the size of a 2-euro coin
- +1 more outcomes
Companies that use PreEvnt
Customer profileSegments4 records
Ideal customer profiles3 records
PreEvnt technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability2 records
Feature4 records
PreEvnt partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Indiana UniversitycoreMulti-year collaboration with Indiana University under the direction of Dr. M. Agarwal. Scientists, designers, and engineers from the university supported years of scientific research and development for Isaac's breath analysis technology. The university is also conducting human clinical trials for the device.
- NanozcoreNanoz provides its patented selective gas-sensing MOx technology that Isaac uses for VOC/acetone detection in breath analysis. This is a technology licensing arrangement for the core sensing technology.
- Scosche IndustriescorePreEvnt is a subsidiary of Scosche Industries, headquartered in Oxnard, California. Scosche revealed PreEvnt as its health tech subsidiary at CES 2025, providing corporate backing and parent company resources.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
PreEvnt competitors and assessment
Company assessmentEmerging players
- Biolinq: Developer of intradermal biosensor patches for continuous metabolic monitoring including glucose. Adjacent wearable biosensor competitor pursuing miniaturized, minimally invasive alternatives to traditional CGMs.
- Levels Health: Consumer metabolic health platform that combines CGM hardware with a software subscription for insights. Competitor for the same health-conscious consumer segment that Isaac targets with its app-driven experience.
- Afon Technology: UK-based developer of a non-invasive wearable continuous glucose monitor. Direct non-invasive glucose monitoring peer, both competing to bring the first needle-free CGM alternative to market.
- Know Labs: Public company developing a non-invasive glucose monitor (KnowU, UBand) using radiofrequency spectroscopy. Direct competitor in the non-invasive glucose monitoring space, with similar pre-FDA / pre-commercial status.
- Nutrix: Swiss-based developer of Corti, a non-invasive saliva-based continuous glucose monitor. Direct non-invasive glucose monitoring peer pursuing an alternative biosensing approach to the same end market.
- Stelo (Dexcom spin-out): Dexcom's OTC consumer glucose monitor launched for non-insulin-using prediabetics and health-conscious consumers. Most direct overlap with Isaac's OTC / wellness positioning at a lower regulatory bar than prescription CGMs.
Broad incumbents
- Medtronic: Large incumbent diabetes care company with CGM systems (Guardian) integrated with insulin pumps. Competes in the same endocrinologist-prescribed diabetes management workflow that Isaac targets as an OTC alternative.
- Apple: Apple Watch includes blood glucose trend tracking features and Apple has publicly explored non-invasive glucose monitoring. Represents the biggest potential platform threat if a major consumer electronics incumbent enters the non-invasive glucose category.
Direct peers
- Dexcom: Leading continuous glucose monitor (CGM) manufacturer with FDA-cleared G-series devices. Isaac competes for the same patient population (T1D, T2D, prediabetes) using a non-invasive alternative to Dexcom's minimally invasive CGM.
- Abbott: Manufacturer of the FreeStyle Libre CGM, the dominant consumer/semi-prescription CGM brand globally. Isaac's value proposition explicitly contrasts against Abbott's finger-prick-free positioning, making them the most direct competitor.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
PreEvnt social profiles
Digital presencePreEvnt financial estimates
Financial estimateRevenue estimate
Valuation estimate
PreEvnt leadership team
Management profileNumber of profiles
Profiles1 record
PreEvnt funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PreEvnt M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PreEvnt
What does PreEvnt do?
PreEvnt develops, manufactures (via parent Scosche Industries), and intends to sell "isaac," a non-invasive, wearable breath-based glucose-monitoring device that detects acetone (a VOC) in exhaled breath to alert users to elevated blood glucose levels without finger-prick blood tests. It is paired with a free iOS/Android companion app that logs readings, dispatches real-time alerts (including to emergency contacts), and exports shareable reports. The product is not yet commercially available as it is undergoing FDA De Novo review, with human clinical trials at Indiana University Indianapolis supporting the regulatory pathway.
Is PreEvnt a public or private company?
PreEvnt is a private company. It is classified as corporate owned and is currently operating.
When was PreEvnt founded?
PreEvnt was founded in 2024. It employs 1 to 10 people.
Where is PreEvnt based?
PreEvnt is headquartered in Oxnard, United States, in the North America region.
How does PreEvnt make money?
Two revenue lines are on record. Hardware Device Sales are the primary driver. The others are mobile Application Services.
Who are PreEvnt's main competitors?
Emerging players on record are Biolinq, Levels Health, Afon Technology, Know Labs, Nutrix and Stelo (Dexcom spin-out). Broad incumbents are Medtronic and Apple. Direct peers are Dexcom and Abbott.
Does PreEvnt have an API?
No public API is recorded for PreEvnt.
What industry is PreEvnt in?
PreEvnt's product category is Non-Invasive Glucose Monitoring Devices. Its primary akta.pro industry code is CRACAQAE, Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers), with a secondary code of HLAKADAA, Diabetes (General). Its NAICS code is 334510 and its SIC code is 2835.